JBS 4Q25 presentation: record $86B revenue masks margin pressure

Revenue of $86.2B (+11.7% YoY) and net income of $2.024B (+14.5% YoY; EPS $1.89) contrasted sharply with collapsing free cash flow of $400M (‑83% YoY) and adjusted EBITDA margin compression to 7.9% from 9.3%. Shares reacted positively (up 7.46% to $15.75) on the NYSE-listed milestone and top-line beat, but operating cash flow fell to $4.046B and capex rose to $2.099B, pressuring liquidity despite $4.77B cash and net debt of $16.32B (net leverage 2.39x). Management gave 2026 targets (EPS $0.35–$0.55; revenue ~$88.23B) and flagged commodity, supply-chain and regulatory risks; the key watch is whether margins and free cash flow recover as expansion and M&A continue.

Analysis

JBS’s scale and multi-protein footprint create optionality other processors lack: management can re-route production and inventory between geographies to smooth cyclical shocks, but that same flexibility masks localized margin damage and delays price discovery. Expect margin recovery to be lumpy — improvements in one region can be offset by input-cost inflation or sanitary events elsewhere, meaning headline revenue beats will likely continue to coexist with volatile operating cash conversion.

Capital allocation is the fulcrum. Aggressive expansion into lower-cost producing regions and the NY listing materially increase the firm’s ability to fund growth with equity, which reduces refinancing risk but raises dilution and governance timing risk; near-term management choices (pause buybacks, prioritize maintenance capex, or accelerate asset sales) will be the clearest signal of financial conservatism versus growth-aggression. Credit-market reaction will be sensitive to quarter-to-quarter cash flow swings rather than long-dated maturities, so spreads could move more on operational noise than on true solvency dynamics.

Key catalysts to watch are input-cost trajectories (corn/soymeal and regional cattle cycles), a change in U.S. beef wholesale realizations, and discrete capital-allocation announcements (large divestitures or equity raises). Tail risks include contagious livestock disease events or a material swing in export demand from large buyers — these can compress margins quickly and force strategic reversals. A successful margin inflection will likely play out over 3–12 months as working capital normalizes and new capacity comes online in low-cost regions; absent that, downside is concentrated in deteriorating cash conversion and capital-returns cuts.

Key Decisions for Investors

• Long JBS (JBS) conditional entry: accumulate on an 8–12% intraday pullback from today’s price using a 12–18 month horizon. Hedge with 25% OTM puts (same tenor) to cap downside; R/R: aim for +35–50% if margins normalize and market re-rates scale, risk is ~-25–35% if cash conversion deteriorates further.
• Relative-value pair: long JBS (JBS) / short Tyson Foods (TSN) for 6–12 months — size to neutralize protein exposure (dollar-neutral). Thesis: JBS’s geographic optionality and expansion into lower-cost regions should outperform US-centric peers if global beef/poultry mix normalizes; risk if US beef recovery favors TSN, cap losses to a targeted 15–20% of position notional.
• Credit play: buy senior JBS paper in the 5–7 year part of the curve or equivalent CDS protection inversion trade with a 12–24 month horizon. Trade the basis: deploy on spread widenings expecting 100–200bp tightening should margins rebound; downside is mark-to-market losses if operational cash flow deteriorates and spreads widen further.
• Event/options tactical: buy 12–18 month call spreads on JBS sized for 1–2% portfolio exposure ahead of the next quarterly update and any capital-allocation decision. Cap premium by using verticals; objective is to capture asymmetric upside from a clearer path to FCF recovery while limiting premium decay.